NMDA receptor hypofunction induces dysfunctions of energy metabolism and semaphorin signaling in rats: A synaptic proteome study

Schizophrenia Bulletin

Volumn 38, Issue 3, 2012, Pages 579-591

  Zhou, Kejun ^a,b   Yang, Yifeng ^a,b   Gao, Linghan ^a,b   He, Guang ^a,b   Li, Weidong ^a,b   Tang, Kefu ^a,b   Ji, Baohu ^a,b   Zhang, Ming ^a,b   Li, Yang ^a,b   Yang, Jinglei ^a,b   Sun, Liya ^a,b   Zhang, Zhao ^a,b   Zhu, Hui ^a,b   He, Lin ^a,b,c   Wan, Chunling ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

MK 801; NMDA; proteomics; schizophrenia; synaptosome

Indexed keywords

DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEOME; SEMAPHORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN SYNAPTOSOME; CELL INTERACTION; CELL STRUCTURE; ENERGY METABOLISM; INTRACELLULAR SIGNALING; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFECT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN ISOLATION; RAT; SYNAPTIC TRANSMISSION; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

ANIMALS; DIZOCILPINE MALEATE; ENERGY METABOLISM; PROTEOME; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SEMAPHORINS; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SYNAPSES;

EID: 84860159426     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbq132     Document Type: Article

References (74)

1. Mirnics K, Middleton FA, Lewis DA, Levitt P. Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse. Trends Neurosci. 2001;24:479-486. (Pubitemid 32695360)
2. Frankle WG, Lerma J, Laruelle M. The synaptic hypothesis of schizophrenia. Neuron. 2003;39:205-216. (Pubitemid 36897544)
3. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of selfmonitoring. Schizophr Bull. 2009;35:509-527.
4. Khvotchev M. Schizophrenia and synapse: emerging role of presynaptic fusion machinery. Biol Psychiatry. 2010;67:197-198.
5. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry. 2005;10:40-68 image 45. (Pubitemid 40139588)
6. Lang UE, Puls I, Muller DJ, Strutz-Seebohm N, Gallinat J. Molecular mechanisms of schizophrenia. Cell Physiol Biochem. 2007;20:687-702. (Pubitemid 350059714)
7. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006;12:824-828.
8. Kehrer C, Maziashvili N, Dugladze T, Gloveli T. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front Mol Neurosci. 2008;1:6.
9. Mouri A, Noda Y, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int. 2007;51:173-184. (Pubitemid 47176714)
10. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev. 2009;60: 279-286.
11. Li B, Devidze N, Barengolts D, et al. NMDA receptor phosphorylation at a site affected in schizophrenia controls synaptic and behavioral plasticity. J Neurosci. 2009;29: 11965-11972.
12. Pennington K, Beasley CL, Dicker P, et al. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry. 2008;13:1102-1117.
13. Andine P, Widermark N, Axelsson R, et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther. 1999;290:1393-1408. (Pubitemid 29400285)
14. Rung JP, Carlsson A, Ryden Markinhuhta K, Carlsson ML. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:827-832. (Pubitemid 40897800)
15. Paulson L, Martin P, Persson A, et al. Comparative genomeand proteome analysis of cerebral cortex from MK-801-treated rats. J Neurosci Res. 2003;71:526-533. (Pubitemid 36158336)
16. Paulson L, Martin P, Ljung E, Blennow K, Davidsson P. Effects on rat thalamic proteome by acute and subchronic MK-801-treatment. Eur J Pharmacol. 2004;505:103-109. (Pubitemid 39535681)
17. Paulson L, Martin P, Nilsson CL, et al. Comparative proteome analysis of thalamus in MK-801-treated rats. Proteomics. 2004;4:819-825. (Pubitemid 38339159)
18. Booth RF, Clark JB. A rapid method for the preparation of relatively pure metabolically competent synaptosomes from rat brain. Biochem J. 1978;176:365-370. (Pubitemid 9061168)
19. Ma D, Chan MK, Lockstone HE, et al. Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res. 2009;8:3284-3297.
20. Deighton RF, Kerr LE, Short DM, Allerhand M, Whittle IR, McCulloch J. Network generation enhances interpretation of proteomic data from induced apoptosis. Proteomics. 2010;10:1307-1315.
21. Collins MO, Husi H, Yu L, et al. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J Neurochem. 2006;97(suppl 1):16-23.
22. Abul-Husn NS, Bushlin I, Moron JA, et al. Systems approach to explore components and interactions in the presynapse. Proteomics. 2009;9:3303-3315.
23. Morciano M, Beckhaus T, Karas M, Zimmermann H, Volknandt W. The proteome of the presynaptic active zone: from docked synaptic vesicles to adhesion molecules and maxi-channels. J Neurochem. 2009;108:662-675.
24. Phillips GR, Florens L, Tanaka H, et al. Proteomic comparison of two fractions derived from the transsynaptic scaffold. J Neurosci Res. 2005;81:762-775. (Pubitemid 41532142)
25. Takamori S, Holt M, Stenius K, et al. Molecular anatomy of a trafficking organelle. Cell. 2006;127:831-846. (Pubitemid 44716256)
26. Fernandez E, Collins MO, Uren RT, et al. Targeted tandem affinity purification of PSD-95 recovers core postsynaptic complexes and schizophrenia susceptibility proteins. Mol Syst Biol. 2009;5:269.
27. Husi H, Ward MA, Choudhary JS, BlackstockWP, Grant SG. Proteomic analysis of NMDA receptor-adhesion protein signaling complexes. Nat Neurosci. 2000;3:661-669. (Pubitemid 30437200)
28. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry. 2009;9:17.
29. Clark D, Dedova I, Cordwell S, Matsumoto I. Altered proteins of the anterior cingulate cortex white matter proteome in schizophrenia. Proteomics. 2007;1:155-166.
30. Ben-Shachar D, Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression. PLoS One. 2008;3:e3676.
31. Patterson EE, Minor KM, Tchernatynskaia AV, et al. A canine DNM1 mutation is highly associated with the syndrome of exercise-induced collapse. Nat Genet. 2008;40:1235-1239.
32. Clark D, Dedova I, Cordwell S, Matsumoto I. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry. 2006;11:459-470, 423.
33. Prabakaran S, Swatton JE, Ryan MM, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004;9:684-697, 643. (Pubitemid 38932173)
34. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res. 2009;43:978-986.
35. Sheu KF, Brown AM, Kristal BS, et al. A DLST genotype associated with reduced risk for Alzheimer's disease. Neurology. 1999;52:1505-1507. (Pubitemid 29190553)
36. English JA, Dicker P, Focking M, Dunn MJ, Cotter DR. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics. 2009;9:3368-3382.
37. Shyn SI, Shi J, Kraft JB, et al. Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies [published online ahead of print December 29, 2009]. Mol Psychiatry doi:10.1038/mp.2009.125.
38. George AJ, Gordon L, Beissbarth T, et al. A serial analysis of gene expression profile of the Alzheimer's disease Tg2576 mouse model. Neurotox Res. 2010;17:360-379.
39. Martins-de-Souza D, Gattaz WF, Schmitt A, et al. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2009;259:151-163.
40. Benit P, Slama A, Cartault F, et al. Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome. J Med Genet. 2004;41:14-17. (Pubitemid 38125680)
41. Olsen L, Hansen T, Jakobsen KD, et al. The estrogen hypothesis of schizophrenia implicates glucose metabolism: association study in three independent samples. BMC Med Genet. 2008;9:39.
42. Wang YJ, Chen GH, Hu XY, Lu YP, Zhou JN, Liu RY. The expression of calcium/calmodulin-dependent protein kinase II-alpha in the hippocampus of patients with Alzheimer's disease and its links with AD-related pathology. Brain Res. 2005;1031:101-108.
43. Novak G, Seeman P, Tallerico T. Increased expression of calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in schizophrenia and depression. Synapse. 2006;59:61-68. (Pubitemid 41706155)
44. Vawter MP, Ferran E, Galke B, Cooper K, Bunney WE, Byerley W. Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res. 2004;67:41-52. (Pubitemid 38117090)
45. Fallin MD, Lasseter VK, Avramopoulos D, et al. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet. 2005;77:918-936. (Pubitemid 41698514)
46. Pennington K, Dicker P, Dunn MJ, Cotter DR. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics. 2008;8: 5097-5107.
47. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for diseaseassociated changes. Proteomics. 2006;6:3414-3425. (Pubitemid 43886157)
48. Martin MA, Blazquez A, Gutierrez-Solana LG, et al. Leigh syndrome associated with mitochondrial complex I deficiency due to a novel mutation in the NDUFS1 gene. Arch Neurol. 2005;62:659-661. (Pubitemid 40489902)
49. Daoud H, Gruchy N, Constans JM, et al. Haploinsufficiency of the GPD2 gene in a patient with nonsyndromic mental retardation. Hum Genet. 2009;124:649-658.
50. Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005;272:4211-4220. (Pubitemid 41160927)
51. Goldman JG, Goetz CG, Berry-Kravis E, Leurgans S, Zhou L. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol. 2004;61:1280-1284. (Pubitemid 39062685)
52. Bernard R, Kerman IA, Thompson RC, et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression [published online ahead of print April 13, 2010]. Mol Psychiatry. doi:10.1038/mp.2010.44.
53. Weickert CS, Sheedy D, Rothmond DA, et al. Selection of reference gene expression in a schizophrenia brain cohort. Aust N Z J Psychiatry. 2010;44:59-70.
54. Brown AM, Gordon D, Lee H, et al. Association of the dihydrolipoamide dehydrogenase gene with Alzheimer's disease in an Ashkenazi Jewish population. Am J Med Genet B Neuropsychiatr Genet. 2004;131B:60-66. (Pubitemid 39458439)
55. Coba MP, Pocklington AJ, Collins MO, et al. Neurotransmitters drive combinatorial multistate postsynaptic density networks. Sci Signal. 2009;2:ra19.
56. Roth L, Koncina E, Satkauskas S, Cremel G, Aunis D, Bagnard D. The many faces of semaphorins: from development to pathology. Cell Mol Life Sci. 2009;66:649-666.
57. Raveendran R, Devi Suma Priya S, Mayadevi M, et al. Phosphorylation status of the NR2B subunit of NMDA receptor regulates its interaction with calcium/calmodulin-dependent protein kinase II. J Neurochem. 2009;110:92-105.
58. Takahashi E, Niimi K, Itakura C. Enhanced CaMKII activity and spatial cognitive function in SAMP6 mice. Behav Neurosci. 2009;123:527-532.
59. Chen C, Rainnie DG, Greene RW, Tonegawa S. Abnormal fear response and aggressive behavior in mutant mice deficient for alpha-calcium-calmodulin kinase II. Science. 1994;266:291-294. (Pubitemid 24343517)
60. Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009;15:1407-1413.
61. Auerbach W, Hurlbert MS, Hilditch-Maguire P, et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet. 2001;10:2515-2523. (Pubitemid 33095002)
62. Gauthier LR, Charrin BC, Borrell-Pages M, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118:127-138. (Pubitemid 38902819)
63. Leavitt BR, van Raamsdonk JM, Shehadeh J, et al. Wildtype huntingtin protects neurons from excitotoxicity. J Neurochem. 2006;96:1121-1129.
64. Ben-Shachar D. The interplay between mitochondrial complex I, dopamine and Sp1 in schizophrenia. J Neural Transm. 2009;116:1383-1396.
65. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem Res. 2009;34:1021-1029.
66. Dwyer DS, Weeks K, Aamodt EJ. Drug discovery based on genetic and metabolic findings in schizophrenia. Expert Rev Clin Pharmacol. 2008;1:773-789.
67. Eastwood SL, Law AJ, Everall IP, Harrison PJ. The axonal chemorepellant semaphorin 3A is increased in the cerebellum in schizophrenia and may contribute to its synaptic pathology. Mol Psychiatry. 2003;8:148-155. (Pubitemid 36315223)
68. Mah S, Nelson MR, Delisi LE, et al. Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia. Mol Psychiatry. 2006;11:471-478.
69. Watanabe T, Iwasaki K, Takasaki K, et al. Dynamin 1 depletion and memory deficits in rats treated with Abeta and cerebral ischemia. J Neurosci Res. 2010;88:1908-1917.
70. Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA. 1998;95:7240-7244. (Pubitemid 28293235)
71. Wan C, Shi Y, Zhao X, et al. Positive association between ALDH1A2 and schizophrenia in the Chinese population. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1491-1495.
72. Lerner V, Miodownik C, Gibel A, et al. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clin Neuropharmacol. 2008;31:25-33. (Pubitemid 351321438)
73. Ethier I, Beaudry G, St-Hilaire M, Milbrandt J, Rouillard C, Levesque D. The transcription factor NGFI-B (Nur77) and retinoids play a critical role in acute neuroleptic-induced extrapyramidal effect and striatal neuropeptide gene expression. Neuropsychopharmacology. 2004;29:335-346. (Pubitemid 38175152)
74. Ethier I, Kagechika H, Shudo K, Rouillard C, Levesque D. Docosahexaenoic acid reduces haloperidol-induced dyskinesias in mice: involvement of Nur77 and retinoid receptors. Biol Psychiatry. 2004;56:522-526. (Pubitemid 39278251)